Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2006-05-16
2006-05-16
Nashed, Nashaat T. (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S183000, C435S215000, C514S002600, C530S350000
Reexamination Certificate
active
07045280
ABSTRACT:
The present invention provides a method for the measurement of the activity of a plasminogen activator, such as urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA) in a biological sample using an assay method characterized by the inclusion of an elastase inhibitor in the assay mixture. The invention also provides a diagnostic kit for the measurement of a plasminogen activator using said method and a method of determining the effective therapeutic dose of a plasminogen activator inhibitor using said method. Also provided is a method of preparing a pharmaceutical composition.
REFERENCES:
patent: 4910190 (1990-03-01), Bergeson et al.
patent: 5955284 (1999-09-01), Braxton et al.
Sugimori et al. Inhibitory Properties of Recombinant Human Monocyte/Neutrophil Elastase Inhibitor (Sep. 1995) Am. J. Respir Cell Molec. Biol. vol. 13, pp. 314-322.
Nicolini et al. Leukocyte elastase inhibition and t-PA-induced coronary artery thrombolysis in dogs: Beneficial effects on myocardial histology (Nov. 1991) vol. 122, No. 5, pp. 1245-1251.
Gilboa et al. Evidence for Regulation of Endothelial Plasminogen-Activating System by Polymorphonuclear Leukocyte Elastase (1989) vol. 54, pp. 467-475.
Mazar et al. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis (1999 Angiogenesis vol. 3, pp. 15-32.
Bach-Gansmo et al., “Degradation of the a-Chain of Fibrin by Human Neutrophil Elastase Reduces the Stimulating Effect of Fibrin on Plasminogen Activation”, Thrombosis Research, vol. 75, No. 3, pp. 307-317, 1994.
Banda et al, “The Role of Macrophage Elastase in the Proteolysis of Fibrinogen, Plasminogen, and Fibronectin”, Federation Proceedings 39(6), Abstract 804.
Chung, et al., “Factors That Control Extravascular Fibrinolysis”, Seminars in Thrombosis and Hemostasis, vol. 22, No. 6, pp. 479-488, 1996.
Dunbar, et al., “Cancer Treatment with Inhibitors of Urokinase-Type Plasminogen Activator and Plasmin”, Ashley Publications Ltd. ISSN 1354-3784, pp. 2085-2092; 2000.
Gilboa, et al., “Neutrophil Elastase Modulates the Plasminogen Activating System of Cultured Rat Mesangial Cells”, Clinical Research, vol. 40, No. 2, p. 319A, 1992.
Heiden et al., “The Role of Inflammatory Cells and Their Proteases in Extravascular Fibrinolysis”, Seminars in Thrombosis and Hemostasis, vol. 22, No. 6, pp. 497-501, 1996.
Kanayama et al., “Inactivation of Human Tumor Cell Pro-urokinase by Granuloctye Elastase”, Jpn J. Cancer Res. 81, 994-1002, Oct. 1990.
Kikuchi, et al., “Adjuvant Effects of Tranexamic Acid to Chemotherapy in Ovarian Cancer Patients with Large Amount of Ascites”, Acta Obstet Gynecol Scand, 65:453-456, 1996.
Lentschener, et al., “Intraoperatively-adminstered aprotinin and survival after elective liver resection for colorectal cancer metastasis—A preliminary study”, Fibrinolysis & Proteolysis (1999) 13 (1), 39-45.
Machovich et al., “An Elastase-Dependent Pathway of Plasminogen Activation”, Biochemistry 28, pp. 4517-4522, 1989.
Machovich et al., “The Elastase-Mediated Pathway of Fibrinolysis”, Blood Coagualtion and Fibrinolysis, 1 pp. 79-90, 1990.
Nagamatsu et al., “Effects of Human Granulocyte Elastase on Fibrinolysis”, Chem. Pharm. Bull. 29 (4) 1121-1129 (1981).
Serdengecti, et al., “Overal Survival Results of Non-Small Cell Lung Cancer Patients: Chemotherapy Alone Versus Chemotherapy with Combined Immunomodulation”, Chemioterapia, vol. 7—n. 2 (122-126), 1998.
Simon et al., “Fibrin(ogen) is Internalized and Degraded by Activated Human Monocytoid Cells Via Mac-1 (CD11b/CD18): A Nonplasmin Fibrinolytic Pathway”, Bood, vol. 82, No. 8, Oct. 15, 1993, pp. 2414-2422.
Simon et al, “The Fibrin(ogen)alytic Properties of Cathepsin D”, Biochemistry 33, pp. 6555-6563, 1994.
Simon et al., “Mac-1 (CD11b/CD18) and the Urokinase Receptor (CD87) Form a Functional Unit on Monocytic Cells”, Blood, vol. 88, No. 8, Oct. 15, 1996, pp. 3185-3194.
Soma, et al, “Treatment of Advanced Ovarian Cancer with Fibrinolytic Inhibitor (Tranexamic Acid)”, Acta Obstet Gynecol Scand 59:285-287, 1980.
Toki et al., “Studies of the Activation Mechanism of Fibrinolytic Enzyme System in Plasma by Human Pancreatic Elastase”, Thromb Haemostas (Stuttgart) 47 (1) 8-13 (1982).
Urano, et al., “Novel Mechanism to Enhance tPA-Induced Fibrinolysis: Effect of Limited Proteolysis of PAI-1 by Neutrophil Elastase”, Polish Journal of Pharmacology, 48, pp. 209-213; 1996.
Vassalli et al., “Amiloride Selectively Inhibits the Urokinase-Type Plasminogen Activator”, Federation of European Biochemical Societies, vol. 214, No. 1, 187-191, Apr. 1987.
Wojta et al., “Evaluation of Fibrinolytic Capacity in Plasma during Thrombolytic Therapy with Single (scu-PA) or Two-Chain Urokinase Type Plasminogen Activator (tcu-PA) by a Combined Assay System for Urokinase Type Plasminogen Activator Antigen and Function”, Thrombosis and Haemostasis 61 (2) pp. 289-293, 1989.
Wu et al., “The Cleavage and Inactivation of Plasminogen Activator Inhibitor Type 1 by Neutrophil Elastase: The Evaluation of Its Physiologic Relevance in Fibrinolysis”, Blood, Nol 86, No. 3, pp. 1056-1061, Aug. 1, 1995.
Elvin Paul
Pinder Philip Edwin
AstraZeneca AB
Fish & Neave IP Group Ropes & Gray LLP
Nashed Nashaat T.
Schnizer Holly
LandOfFree
Assay method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3615392